ROM1 — Rod outer segment membrane protein 1

The ROM1 gene provides instructions for making a protein that is essential for the health and function of the retina, the light-sensitive tissue at the back of the eye. Specifically, the ROM1 protein is found in photoreceptors, the specialized cells that capture light. Inside these cells, the protein helps build and maintain the structure of tiny, flattened sacs called disks, which house the light-sensing machinery. ROM1 works closely with another protein called peripherin-2 to keep these disks properly shaped and organized, which is crucial for normal vision. When there is a mutation in the ROM1 gene, the structure of the photoreceptor disks can become unstable. Interestingly, having a mutation in just one copy of the ROM1 gene usually does not cause vision problems on its own. However, if a person inherits a mutation in the ROM1 gene along with a mutation in the peripherin-2 (PRPH2) gene, it leads to a condition called digenic retinitis pigmentosa. This is a rare type of inheritance where mutations in two different genes are required to cause the disease. For patients and families, this means that retinitis pigmentosa caused by ROM1 involves a progressive loss of vision, typically starting with night blindness and gradually affecting peripheral (side) vision. Because the disease requires mutations in two separate genes, the way it is passed down through families can be complicated. Genetic testing and counseling are very important to understand the specific risks for family members and to confirm the diagnosis.

Gene description: Encodes a structural protein of rod photoreceptor outer segment disc membranes.

Patient and family guide: The ROM1 gene provides instructions for making a protein that is essential for the health and function of the retina, the light-sensitive tissue at the back of the eye. Specifically, the ROM1 protein is found in photoreceptors, the specialized cells that capture light. Inside these cells, the protein helps build and maintain the structure of tiny, flattened sacs called disks, which house the light-sensing machinery. ROM1 works closely with another protein called peripherin-2 to keep these disks properly shaped and organized, which is crucial for normal vision. When there is a mutation in the ROM1 gene, the structure of the photoreceptor disks can become unstable. Interestingly, having a mutation in just one copy of the ROM1 gene usually does not cause vision problems on its own. However, if a person inherits a mutation in the ROM1 gene along with a mutation in the peripherin-2 (PRPH2) gene, it leads to a condition called digenic retinitis pigmentosa. This is a rare type of inheritance where mutations in two different genes are required to cause the disease. For patients and families, this means that retinitis pigmentosa caused by ROM1 involves a progressive loss of vision, typically starting with night blindness and gradually affecting peripheral (side) vision. Because the disease requires mutations in two separate genes, the way it is passed down through families can be complicated. Genetic testing and counseling are very important to understand the specific risks for family members and to confirm the diagnosis.

Gene function: ROM1 is a transmembrane protein located in the outer segment disc membranes of rod photoreceptors. It interacts with peripherin-2 (PRPH2) to form stable tetrameric complexes, which are crucial for maintaining the structural integrity and proper morphogenesis of the photoreceptor outer segments, essential for vision.

Protein structure: The ROM1 protein is an integral membrane protein consisting of 351 amino acids with a molecular weight of approximately 37 kDa. It belongs to the tetraspanin family, characterized by four hydrophobic transmembrane alpha-helices. The protein structure includes short intracellular N- and C-termini, a small intracellular loop, and two extracellular (intradiscal) loops: a small loop (EC1) and a larger loop (EC2 or D2 loop). The large intradiscal D2 loop is particularly important as it contains conserved cysteine residues that form intramolecular disulfide bonds, which are crucial for the proper folding and stability of the protein. This loop also mediates the critical intermolecular interactions with peripherin-2 (PRPH2). ROM1 assembles into non-covalent homodimers and forms heterotetramers with PRPH2 dimers. These tetrameric complexes further aggregate into higher-order oligomers that stabilize the extreme curvature of the photoreceptor disk rims.

Molecular function: The ROM1 (Retinal Outer Segment Membrane Protein 1) gene encodes an integral membrane protein that is a critical structural component of the photoreceptor outer segment disks. ROM1 belongs to the tetraspanin family of proteins, characterized by four transmembrane domains. It localizes specifically to the rims of the flattened membranous disks in the outer segments of rod and cone photoreceptors. At the molecular level, ROM1 functions primarily through its interaction with another tetraspanin protein, peripherin-2 (PRPH2). ROM1 and PRPH2 form non-covalent homo- and hetero-oligomeric complexes (dimers and tetramers) that assemble into larger supramolecular structures at the disk rims. These complexes are essential for the morphogenesis, stabilization, and maintenance of the highly curved rim structure of the photoreceptor disks. While PRPH2 is absolutely required for disk formation, ROM1 appears to play a more modulatory role, regulating the size (diameter) of the disks and ensuring their proper compaction and alignment. The interaction between ROM1 and PRPH2 is crucial for the continuous renewal of the outer segments, a process vital for photoreceptor survival and normal vision. Disruption of this complex compromises the structural integrity of the outer segment, leading to photoreceptor degeneration.

Expression pattern: The ROM1 gene is highly specifically expressed in the retina, with its expression restricted almost exclusively to the photoreceptor cells. Within the photoreceptors, the ROM1 protein is localized to the outer segment, specifically at the rim region of the photoreceptor disks. It is found in both rod and cone photoreceptors, although it is predominantly studied in the context of rod outer segments. Developmentally, ROM1 expression begins during the differentiation of photoreceptors and the formation of the outer segments, and it is maintained throughout adulthood. The precise localization at the disk rims is critical for its function in maintaining the structural integrity and curvature of the disks. There are no widely recognized tissue-specific isoforms outside of the retina, underscoring its specialized role in photoreceptor biology.

Mutation spectrum: The mutation spectrum of the ROM1 gene includes a variety of variant types, though they are relatively rare compared to other major IRD genes. The spectrum encompasses missense, nonsense, frameshift (insertions and deletions), and splice-site mutations. Frameshift mutations, such as the 1-bp insertion at codon 114 (c.339dup), are among the most frequently reported pathogenic variants and typically result in a truncated, non-functional protein or lead to nonsense-mediated decay. Currently, there are a few dozen known pathogenic or likely pathogenic variants in ROM1 listed in databases like ClinVar. There are no major, widely recognized hotspot regions, as mutations are distributed across the gene, though many affect the large intradiscal loop which is critical for protein-protein interactions. Founder mutations have not been prominently characterized for ROM1, likely due to the rarity of the variants and the requirement for a second mutation in PRPH2 to manifest the classic digenic disease.

Pathogenic variants: 1. p.Leu114fs (c.339dup) - A frameshift mutation that is one of the most well-known variants associated with digenic retinitis pigmentosa when co-inherited with a PRPH2 mutation. 2. p.Val81fs (c.239dup) - Another frameshift mutation leading to a truncated protein, implicated in digenic RP. 3. p.Arg287Trp (c.859C>T) - A missense variant reported in patients with retinal dystrophy, potentially altering the transmembrane domain structure. 4. p.Gly191Ser (c.571G>A) - A missense mutation located in the critical intradiscal loop, affecting the interaction with PRPH2. 5. p.Leu238fs (c.712del) - A deletion causing a frameshift, leading to loss of function and associated with retinal degeneration.

Clinical significance: Mutations in the ROM1 gene are primarily associated with inherited retinal diseases, most notably retinitis pigmentosa (RP). However, ROM1 is unique in that heterozygous mutations alone are typically insufficient to cause severe disease, often resulting in a very mild or subclinical phenotype. The most well-known clinical manifestation involving ROM1 is digenic retinitis pigmentosa, which occurs when a patient inherits a heterozygous mutation in ROM1 along with a heterozygous mutation in the unlinked PRPH2 (peripherin-2) gene. Patients with digenic RP typically present with classic symptoms of the disease, including night blindness (nyctalopia) in the first or second decade of life, followed by progressive loss of peripheral vision, eventually leading to tunnel vision and central vision impairment. The severity and age of onset can vary, but it generally follows a progressive course typical of RP. In rare cases, homozygous or compound heterozygous mutations in ROM1 have been reported to cause autosomal recessive retinitis pigmentosa, which tends to be more severe and earlier in onset than the digenic form. ROM1 variants have also been implicated as genetic modifiers that can influence the severity of phenotypes caused by mutations in other retinal genes, such as ABCA4.

Inheritance: Autosomal dominant, digenic

Chromosomal location: 11q13

Genotype-phenotype correlations: Genotype-phenotype correlations for ROM1 are complex due to its frequent role in digenic inheritance and as a genetic modifier. Heterozygous loss-of-function mutations (such as frameshifts or nonsense mutations) in ROM1 generally do not cause a discernible clinical phenotype on their own. However, when combined with a heterozygous mutation in PRPH2, they result in digenic retinitis pigmentosa. The severity of the digenic phenotype can be influenced by the specific nature of the PRPH2 mutation. In the rare instances of homozygous ROM1 mutations, patients typically present with a more severe, early-onset autosomal recessive retinitis pigmentosa. Furthermore, certain missense variants in ROM1 have been suggested to act as disease modifiers, potentially exacerbating the phenotype of patients with mutations in other IRD genes like ABCA4 or PRPH2. The presence of a ROM1 variant can shift a milder macular dystrophy phenotype towards a more severe, widespread retinal degeneration, highlighting the gene's role in the broader genetic landscape of retinal dystrophies.

Research and therapeutic approaches: Currently, there are no FDA-approved therapies specifically targeting ROM1-associated retinal diseases. Management of the condition focuses on supportive care, including low vision aids, regular monitoring, and genetic counseling. Because ROM1 mutations often cause disease in a digenic manner with PRPH2, therapeutic strategies must consider the complex interaction between these two proteins. In the research pipeline, gene therapy is a primary area of investigation for inherited retinal diseases. For ROM1/PRPH2 digenic retinitis pigmentosa, gene augmentation therapy aims to deliver functional copies of the affected genes to the photoreceptors using adeno-associated virus (AAV) vectors. However, because the stoichiometry (the precise ratio) of ROM1 and PRPH2 is critical for normal disk formation, simply overexpressing one or both genes can be toxic to the retina. Therefore, careful regulation of gene expression levels is a major hurdle being addressed in preclinical models. Other investigational approaches include neuroprotective agents to slow photoreceptor degeneration and, in the longer term, CRISPR/Cas9 gene editing to correct specific mutations at the DNA level.

Diagnostic testing: Diagnostic testing for ROM1 mutations is typically performed as part of a comprehensive inherited retinal disease (IRD) next-generation sequencing (NGS) panel. Because ROM1 mutations often cause disease in a digenic manner (in combination with PRPH2 mutations) or act as disease modifiers, it is crucial that genetic testing includes a broad panel of IRD genes rather than single-gene analysis. Whole exome sequencing (WES) or whole genome sequencing (WGS) may also be utilized, particularly in complex cases where a panel does not yield a definitive diagnosis. Genetic counseling is essential for patients with ROM1 variants due to the complex inheritance patterns. If a patient is found to have a heterozygous ROM1 mutation, testing of the PRPH2 gene is imperative to assess the risk of digenic retinitis pigmentosa. Counselors must explain that a single ROM1 mutation may not cause disease on its own, but can be passed to offspring who might develop the disease if they also inherit a PRPH2 mutation from the other parent. This non-Mendelian inheritance requires careful pedigree analysis and clear communication regarding recurrence risks.

Animal models: Animal models have been instrumental in understanding the role of ROM1 in retinal health and disease. The most significant model is the Rom1 knockout mouse (Rom1-/-). These mice exhibit highly disorganized rod outer segments with abnormally large disks, demonstrating that ROM1 is essential for regulating disk size and maintaining the structural integrity of the photoreceptor outer segment. Despite these structural abnormalities, the mice show only a slow, progressive degeneration of photoreceptors, which aligns with the relatively mild phenotype often seen in humans with ROM1 variants alone. Additionally, double heterozygous mice carrying one mutant allele of Prph2 (such as the rds or specific knock-in mutations) and one mutant allele of Rom1 have been used to model digenic retinitis pigmentosa. These models confirm that a reduction in ROM1 exacerbates the structural and functional deficits caused by PRPH2 mutations, leading to more severe photoreceptor degeneration than either mutation alone. These studies underscore the critical, yet partially redundant, roles of ROM1 and PRPH2 in outer segment morphogenesis.

Population genetics: Pathogenic variants in the ROM1 gene are rare in the general population. Because heterozygous ROM1 mutations typically do not cause disease independently, they may exist at very low frequencies in the population without being clinically detected. The prevalence of digenic retinitis pigmentosa caused by combined ROM1 and PRPH2 mutations is extremely low, accounting for only a small fraction (estimated at less than 1-2%) of all retinitis pigmentosa cases. There is no strong evidence of significant founder effects or specific populations with a markedly higher carrier frequency for ROM1 mutations, though comprehensive large-scale population studies specifically targeting ROM1 are limited.

Selected references: 1. Kajiwara K, et al. Digenic retinitis pigmentosa due to mutations at the unlinked peripherin/RDS and ROM1 loci. Science, 1994. PMID: 8202715 2. Dryja TP, et al. Dominant and digenic mutations in the peripherin/RDS and ROM1 genes in retinitis pigmentosa. Invest Ophthalmol Vis Sci, 1997. PMID: 9331261 3. Bascom RA, et al. Mutation analysis of the ROM1 gene in retinitis pigmentosa. Hum Mol Genet, 1995. PMID: 8595413 4. Clarke G, et al. Rom-1 is required for rod photoreceptor viability and the regulation of disk morphogenesis. Nat Genet, 2000. PMID: 10835637 5. Böhm S, et al. Peripherin-2 and Rom-1 have opposing effects on rod outer segment targeting of adRP-linked peripherin-2 mutants. Sci Rep, 2017. PMID: 28538234 6. Conley SM, et al. Rom1 converts Y141C-Prph2-associated pattern dystrophy to retinitis pigmentosa. Hum Mol Genet, 2017. PMID: 28053880